Last checked at 
(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.
Genedrive shares jumped 47% to 5.53 pence each on Wednesday morning in London.
The Manchester, England-based molecular diagnostics company said NICE recommended Genedrive's CYP2C19-ID test as point-of-care test for ischaemic stroke and transient ischaemic attack patients.
The test would be used before administering clopidogrel to manage patients with said conditions to reduce the risk of blood clots that can cause further strokes.
Genedrive's test uses one cheek swab sample and identifies six important genetic variants of the CYP2C19 gene which are important in the loss of metabolism function. Genedrive's system automatically interprets the information for the clinician, helping with administering an optimised treatment plan.
Chief Executive Officer James Cheek said: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for FAST (Face, Arms, Speech, Time) and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect."
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
